Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Hematopoietic Cell Collection

An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor

Bone Marrow Transplantation volume 49, pages 1052–1055 (2014)Cite this article

Subjects

Abstract

In an otherwise eligible patient, inadequate mobilization of PBSCs is a limiting factor to proceeding with an auto-ASCT. In such situations, plerixafor is commonly added to improve PBSC collection yields along with cytokine (G-CSF alone) or chemomobilization (chemotherapy+G-CSF). Individually, both strategies are proven to be safe and effective. Here we report six patients who underwent successful mobilization with combination chemomobilization plus plerixafor after upfront failure of cytokine mobilization plus plerixafor. The median CD34+ cell yield after chemomobilization was 2.48 × 106/kg (range 0.99–8.49) after receiving one to two doses of plerixafor. All patients subsequently underwent ASCT without major unforeseen toxicities and engrafted successfully. No significant delays in time to neutrophil recovery were observed. Our experience highlights the safety and effectiveness of chemomobilization with plerixafor after G-CSF plus plerixafor (G+P) failure and suggests this is a viable salvage strategy after initial failed G+P mobilization.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Sheppard D, Bredeson C, Allan D, Tay J . Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2012; 18: 1191–1203.

    Article  Google Scholar 

  2. Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095–1102.

    Article  CAS  Google Scholar 

  3. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867–1874.

    Article  CAS  Google Scholar 

  4. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767–4773.

    Article  CAS  Google Scholar 

  5. To LB, Levesque JP, Herbert KE . How I treat patients who mobilize hematopoietic stem cells poorly. Blood 2011; 118: 4530–4540.

    Article  CAS  Google Scholar 

  6. Anagnostopoulos I, Hummel M, Kreschel C, Stein H . Morphology, immunophenotype, and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 1995; 85: 744–750.

    CAS  PubMed  Google Scholar 

  7. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331–338.

    Article  CAS  Google Scholar 

  8. Shaughnessy P, Uberti J, Devine S, Maziarz RT, Vose J, Micallef I et al. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program. Bone Marrow Transplant 2013; 48: 777–781.

    Article  CAS  Google Scholar 

  9. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.

    CAS  Google Scholar 

  10. Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G et al. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009; 15: 1578–1586.

    Article  CAS  Google Scholar 

  11. Maziarz RT, Nademanee AP, Micallef IN, Stiff PJ, Calandra G, Angell J et al. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biol Blood Marrow Transplant 2013; 19: 670–675.

    Article  CAS  Google Scholar 

  12. Attolico I, Pavone V, Ostuni A, Rossini B, Musso M, Crescimanno A et al. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma. Biol Blood Marrow Transplant 2012; 18: 241–249.

    Article  CAS  Google Scholar 

  13. Wood WA, Whitley J, Moore D, Sharf A, Irons R, Rao K et al. Chemomobilization with etoposide is highly effective in patients with multiple myeloma and overcomes the effects of age and prior therapy. Biol Blood Marrow Transplant 2011; 17: 141–146.

    Article  CAS  Google Scholar 

  14. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010; 45: 39–47.

    Article  CAS  Google Scholar 

  15. Wood WA, Whitley J, Goyal R, Brown PM, Sharf A, Irons R et al. Effectiveness of etoposide chemomobilization in lymphoma patients undergoing auto-SCT. Bone Marrow Transplant 2013; 48: 771–776.

    Article  CAS  Google Scholar 

  16. Basak GW, Mikala G, Koristek Z, Jaksic O, Basic-Kinda S, Cegledi A et al. Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late. Leuk Lymphoma 2011; 52: 1711–1719.

    Article  CAS  Google Scholar 

  17. D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356–363.

    Article  CAS  Google Scholar 

  18. Hubel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2011; 46: 1045–1052.

    Article  CAS  Google Scholar 

  19. Faison E, Chow E, Khan T, Covington D, Shea T, Rao K . Effectiveness of an algorithm-based approach to filgrastim-based mobilization using predetermined decision points for the inclusion of plerixafor. Biol Blood Marrow Transplant 2013; 19: S175.

    Article  Google Scholar 

  20. Heininger A, Jahn G, Engel C, Notheisen T, Unertl K, Hamprecht K . Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit Care Med 2001; 29: 541–547.

    Article  CAS  Google Scholar 

  21. Jantunen E, Kuittinen T, Mahlamaki E, Pyorala M, Mantymaa P, Nousiainen T . Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol 2011; 86: 299–304.

    Article  CAS  Google Scholar 

  22. Haverkos B, Geyer S, McBride A, Penza S, Devine S, Andritsos L et al. Mobilization for autologous stem cell transplantation in Hodgkin’s lymphoma (HL) and non-Hodgkin lymphoma (NHL): a single institution experience. Biol Blood Marrow Transplant 2014; 20: S111–S112.

    Article  Google Scholar 

  23. Tomblyn M, Burns LJ, Blazar B, Wagner J, Lee C, Rogers T et al. Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphoma. Bone Marrow Transplant 2007; 40: 111–118.

    Article  CAS  Google Scholar 

  24. Gordan LN, Sugrue MW, Lynch JW, Williams KD, Khan SA, Wingard JR et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 815–820.

    Article  CAS  Google Scholar 

  25. Kanate AS, Watkins K, Cumpston A, Craig M, Hamadani M . Salvage bone marrow harvest in patients failing plerixafor-based stem cell mobilization attempt: feasibility and autologous transplantation outcomes. Biol Blood Marrow Transplant 19: 1133–1135.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, The Ohio State University, Columbus, OH, USA

    B M Haverkos, L O'Donnell, D Scholl, B Whittaker, S Vasu, S Penza, L A Andritsos, S M Devine & S M Jaglowski

  2. Department of Pharmacy, The University of Arizona Cancer Center, Tuczon, AZ, USA

    A McBride

Authors
  1. B M Haverkos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A McBride
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L O'Donnell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. D Scholl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Whittaker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Vasu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Penza
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. L A Andritsos
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S M Devine
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S M Jaglowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S M Jaglowski.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haverkos, B., McBride, A., O'Donnell, L. et al. An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor. Bone Marrow Transplant 49, 1052–1055 (2014). https://doi.org/10.1038/bmt.2014.90

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.90

This article is cited by

Search

Advanced search

Quick links